摘要
目的探讨盐酸丁螺环酮片联合利培酮片对稳定期精神分裂症患者阴性症状的疗效。方法选择2014年1月至2016年1月北京市怀柔安佳医院门诊就诊的稳定期精神分裂症患者60例。应用随机数字表将60例患者分为2组,各30例。对照组维持入组时利培酮片治疗剂量,观察组维持入组时利培酮片治疗剂量,基线期评估后开始联合盐酸丁螺环酮片治疗。分别于基线和治疗4、8周末应用阳性与阴性症状量表(PANSS)进行症状评估,以阴性症状量表作为主要疗效指标;应用不良反应量表观察2组患者的药物不良反应。结果 2组患者基线资料比较差异均无统计学意义(均P>0.05)。在基线期,2组PANSS评分比较差异均无统计学意义(均P>0.05)。治疗4周,2组PANSS评分及与本组基线比较差异均无统计学意义(均P>0.05)。治疗8周观察组的阴性症状量表评分低于本组基线期及治疗4周,且低于对照组同时点[(15±4)分比(18±5)、(17±4)、(18±5)分],差异均有统计学意义(均P<0.05)。2组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。结论利培酮片联合盐酸丁螺环酮片对改善稳定期精神分裂症患者阴性症状安全有效。
Objective To observe the effect of buspirone hydrochloride tablets combined with risperidone tablets on negative symptoms of stable schizophrenia. Methods A total of 60 patients with schizophrenia of stable phase in BeiJing Huairou Anjia Hospital from January 2014 to January 2016 were randomly divided into observation group and control group, with 30 cases in each group. The control group was treated with buspirone hydrochloride tablets; the observation group was treated with buspirone hydrochloride tablets combined with risperidone tablets. The Positive and Negative Symptom Scale（PANSS） was used to evaluate the therapeutic effect; the Treatment Emergent Symptom Scale was used to evaluate adverse reactions. Results The PANSS score showed no significant difference between groups before treatment and 4 weeks after treatment（P＞0.05）. Eight weeks after treatment, the negative symptom score in observation group was significantly lower than that before treatment and 4 weeks after treatment; the negative symptom score in observation group was significantly lower than that in control group［（15±4） vs （18±5）,（17±4）,（18±5）］（P〈0.05）. There was no significant difference of incidence of adverse reactions between groups（P〉0.05）. Conclusion Risperidone combined with buspirone hydrochloride is safe and effective in treatment of the negative symptoms of stable schizophrenia.
作者
秦秋红
姜涛
Qin Qiuhong;Jiang Tao(Department of Pschiatry, Beifing Huairou Anjia Hospital, Beijing 101400, China;the 8th Ward, Beifing Anding Hospital, Capital Medical University, Beijing 100088, China)
出处
《中国医药》
2018年第6期866-869,共4页
China Medicine
